NCT03627520View on ClinicalTrials.gov

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

July 1, 2018

Study Completion Date

July 1, 2018

Conditions
Healthy
Interventions
DRUG

[14C]Sulfatinib

300 mg Sulfatinib with 100 µCi \[14C\]

Trial Locations (1)

201203

Hutchison Medipharma Ltd., Shanghai

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT03627520 - A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib | Biotech Hunter | Biotech Hunter